Premium
P‐glycoprotein expression in hepatocellular carcinoma
Author(s) -
Isshiki Koichi,
Nakao Akimasa,
Ito Masafumi,
Hamaguchi Michinari,
Takagi Hiroshi
Publication year - 1993
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930520107
Subject(s) - hepatocellular carcinoma , staining , p glycoprotein , monoclonal antibody , antibody , glycoprotein , medicine , pathology , immunohistochemistry , multiple drug resistance , microbiology and biotechnology , carcinoma , hepatocyte , western blot , liver cancer , membrane glycoproteins , cell , cancer research , biology , drug resistance , immunology , gene , in vitro , biochemistry
Abstract In hepatocellular carcinoma cell lines, the intensity of staining with the monoclonal antibody C‐219 to the multidrug‐resistant gene (mdr1) product P‐glycoprotein and the intensity of the band at a molecular weight of 170 KDa on Western blot were associated closely with resistance to Adriamycin but not with the resistance to cis‐dichlorodiamine platinum (CDDP). In clinical specimens, noncancerous liver tissue was regularly stained with this antibody on the biliary canalicular front of the hepatocyte cell membrane. In liver cancer tissue, however, regular staining as in the noncancerous regions of the liver was observed in only 16% of the patients, irregular staining was seen in only 24%, and no staining was seen at all in 60%. Staining of P‐glycoprotein with the C‐219 antibody is technically simple and is useful for studying the role of P‐glycoprotein in drug‐resistant hepatocellular carcinoma. © 1993 Wiley‐Liss, Inc.